Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin LymphomaReport as inadecuate

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma - Download this document for free, or read online. Document in PDF available to download.

Advances in HematologyVolume 2011 2011, Article ID 656013, 7 pages

Review ArticleDepartment of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA

Received 12 July 2010; Accepted 27 February 2011

Academic Editor: Jorge Enrique Romaguera

Copyright © 2011 Bhanu Vakkalanka and Brian K. Link. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


A combination of Adriamycin a.k.a. Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine ABVD is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter this commonly encountered problem, including dose modification, use of colony stimulating factors, and prophylactic or therapeutic use of antibiotics. Data to support these approaches is somewhat controversial, and in keeping with the paucity of definitive evidence, there is a wide disparity in the management of neutropenia in patients receiving ABVD chemotherapy. This paper summarizes the evidence for managing ABVD-related neutropenia during the treatment of Hodgkin lymphoma.

Author: Bhanu Vakkalanka and Brian K. Link



Related documents